SELLAS Announces Topline Data From Phase 2a Study of SLS009 In Relapsed/Refractory Acute Myeloid Leukemia And Provides Steering Committee Update on Phase 3 REGAL Study
SELLAS Announces Topline Data From Phase 2a Study of SLS009 In Relapsed/Refractory Acute Myeloid Leukemia And Provides Steering Committee Update on Phase 3 REGAL Study
SELLAS 公布了复发/难治性急性髓系白血病 SLS009 2a 期研究的主要数据，并提供了指导委员会关于 REGAL 3 期研究的最新情况
- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April -
- Phase 2a study of SLS009 in r/r AML: 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20%; 100% Response Rate in Patients with Identified Biomarkers to Date -
- Median OS Has Not Been Reached in the Phase 2a Study of SLS009; First CR Patient Continues on Study and Remains Leukemia-Free 9 Months Since Enrollment –
- SLS009 Exhibits Strong Anti-Leukemic Activity in ~70% of Patients with a Favorable Safety Profile at All Dose Levels -
- 反洗钱中全科医生的第三阶段REGAL研究：招生工作已完成；指导委员会指导的中期分析迫在眉睫；IDMC现定于4月下旬进行-
- SLS009 在 r/r 急性髓细胞白血病中的 2a 期研究：在所选最佳剂量 30 mg BIW 中，反应率为 50%，超过目标 20%；迄今为止，已确定生物标志物的患者的反应率为 100%-
- SLS009 的 2a 期研究尚未达到中位操作系统；首位 CR 患者继续研究，自入组 9 个月后仍保持无白血病状态 —
- SLS009 在大约 70% 的患者中表现出强大的抗白血病活性，在所有剂量水平下均具有良好的安全性-